Atlas Trials

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Clinical trial NCT05213312 · UNKNOWN

Trial details

NCT number
NCT05213312
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2022-06-01
Primary completion
2022-11-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.